Navenibart not checked

Astria Therapeutics, Inc. · STAR-0215

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
6 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
How it’s given
“Navenibart will be administered as a subcutaneous injection.”In the company’s words, NCT06842823 on ClinicalTrials.gov
Tested for
Hereditary Angioedema (HAE) (2 trials), Hereditary Angioedema
Main trialPhase 3
“This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.”In the company’s words, NCT06842823 on ClinicalTrials.gov
Other names
STAR-0215 · Autoinjector

Other drugs for Hereditary Angioedema (HAE)

All 8 drugs for Hereditary Angioedema (HAE)

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2026 A Study of Navenibart in Participants With Hereditary Angioedema
Phase 3Enrolling by invitation Jun 2031 A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Phase 2Active, not recruiting Mar 2031 A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Phase 1Recruiting Sep 2026 A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
Phase 1/2Completed 13 Mar 2025 A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
Phase 1Completed 17 Nov 2023 A Study of STAR-0215 in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Navenibart

Following is part of Solo: you see every change to Navenibart the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in